Reader

In the field of IP in molecular diagnostics, is it common for a licensee to build additional, novel IP over and above the core IP and to arg

Current node Origin

In the field of IP in molecular diagnostics, is it common for a licensee to build additional, novel IP over and above the core IP and to argue successfully (both commercially and/or in court) that the novel elements amount to a dilution or diminution in contribution from the original/ core licensed IP, and therefore also to renegotiate royalties when commercialising a product, or the terms of a licence more generally when, say, extending the duration of its licence over the core IP?

Then

Then Answer

Then

Then Related Ideas

Continue this thread

If you want to keep exploring this line of thought, open the editor and add the next question or answer from this endpoint.

Continue this thread in the editor on desktop.

Reading key

Notes

Links